These therapies aim to enhance WL and improve metabolic outcomes by engaging multiple hormonal pathways, with preclinical and early-phase clinical trials supporting their potential as next-generation obesity treatments [16,17,18,19,20,21,22,23]
Interestingly, a new version of GLP-1s known as tirzepatide (Mounjaro) may be more effective than semaglutide
supermarket chain was already seeing an impact on shopping behavior, with patients prescribed Ozempic, Wegovy and other appetite-suppressing medications showing a slight pullback in overall basket. 13 Some analysts are forecasting a 1-3% reduction in annual calorie consumption by the middle of the next decade as a result of the wider uptake of GLP-1RAs
Diabetes indications are often treated differently from obesity indications
ICER has announced they are redoing this analysis (likely with a higher health-benefit price) once the full SELECT results are released
Official Score Breakdown: PlushCare Clinical: 4.8 Support: 4.9 Patient Protection: 4.1 Cost & Value: 4.8 Access: 5.0 Trust & Transparency: 4.5 Authenticity: 5.0 Reputation: 3.2 Official Score Breakdown: Mochi Health Clinical: 4.8 Support: 4.9 Patient Protection: 4.1 Cost & Value: 4.8 Access: 4.7 Trust & Transparency: 5.0 Authenticity: 5.0 Reputation: 4.5 PlushCare: The Primary Care Approach PlushCares clinical quality score of 4.8 reflects a broad medical model rather than a narrow weight-loss funnel
